Multiple Myeloma Clinical Trial

A Study to Evaluate CC-92480, Bortezomib and Dexamethasone (480Vd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Summary

The purpose of this study is to compare the efficacy and safety of CC-92480, bortezomib and dexamethasone (480Vd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Participant has documented diagnosis of MM and measurable disease, defined as any of the following:

M-protein ≥ 0.5 grams per deciliter (g/dL) by serum protein electrophoresis (sPEP) or
M-protein ≥ 200 milligrams (mg) per 24-hour urine collection by urine protein electrophoresis (uPEP)
For participants without measurable disease in sPEP or uPEP: serum free light chain (sFLC) levels > 100 mg/L (10 mg/dL) involved light chain and an abnormal kappa/lambda FLC ratio.
Participants received 1 to 3 prior lines of antimyeloma therapy.
Participants achieved minimal response [MR] or better to at least 1 prior antimyeloma therapy.

Exclusion Criteria:

Participant has had progression during treatment or within 60 days of the last dose of a proteasome inhibitor.
For participants with prior treatment of a bortezomib containing regimen, the best response achieved was not a minimal response (MR) or better, or participant discontinued bortezomib due to toxicity.
Participant has had prior treatment with CC-92480 or pomalidomide.

Other protocol-defined criteria apply.

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

760

Study ID:

NCT05519085

Recruitment Status:

Recruiting

Sponsor:

Bristol-Myers Squibb

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 82 Locations for this study

See Locations Near You

Local Institution
Tucson Arizona, 85724, United States More Info
Site 0076
Contact
Local Institution
Fayetteville Arkansas, 72703, United States More Info
Site 0095
Contact
Yale University School of Medicine
New Haven Connecticut, 06510, United States More Info
Terri Parker, Site 0208
Contact
475-202-9834
University Cancer & Blood Center, LLC
Athens Georgia, 30607, United States More Info
PETROS NIKOLINAKOS, Site 0211
Contact
706-353-2990
Local Institution
Marietta Georgia, 30060, United States More Info
Site 0048
Contact
University of Illinois at Chicago
Chicago Illinois, 60612, United States More Info
Chukwuemeka Uzoka, Site 0265
Contact
312-996-1581
University of Iowa
Iowa City Iowa, 52242, United States More Info
Chris Strouse, Site 0244
Contact
630-917-8956
Tulane Cancer Center
New Orleans Louisiana, 70112, United States More Info
Hana Safah, Site 0255
Contact
504-988-6070
Dana-Farber Cancer Institute
Boston Massachusetts, 02215, United States More Info
Monique Hartley-Brown, Site 0246
Contact
857-299-5736
Hattiesburg Clinic Hematology/Oncology
Hattiesburg Mississippi, 39401, United States More Info
John Hrom, Site 0088
Contact
601-261-1700
The University of Mississippi Medical Center
Jackson Mississippi, 39213, United States
Erie County Medical Center
Buffalo New York, 14215, United States More Info
Naheed Alam, Site 0245
Contact
416-946-4501
Northwell Health Clinical Trials Office
Lake Success New York, 11042, United States More Info
Maria Nieto, Site 0257
Contact
516-734-8900
Duke Cancer Institute
Durham North Carolina, 27710, United States More Info
Cristina Gasparetto, Site 0260
Contact
919-668-1017
WellSpan York Hospital Community Health Center
York Pennsylvania, 17403, United States More Info
Joseph Kannarkatt, Site 0264
Contact
717-741-9229
The West Clinic, PLLC dba West Cancer Center
Germantown Tennessee, 38138, United States More Info
Jason Chandler, Site 0223
Contact
901-683-0055
Mays Cancer Center
San Antonio Texas, 78229, United States More Info
Matthew Butler, Site 0267
Contact
210-450-1818
Utah Cancer Specialists
Salt Lake City Utah, 84106, United States More Info
Stephan Kendall, Site 0207
Contact
801-462-1053
Local Institution
Spokane Washington, 99208, United States More Info
Site 0097
Contact
University of Wisconsin Hospitals and Clinics
Madison Wisconsin, 53792, United States
Local Institution - 0249
Cordoba Córdoba, 5016, Argentina More Info
Site 0249
Contact
Local Institution - 0239
Viedma Río Negro, R8500, Argentina More Info
Site 0239
Contact
Local Institution - 0200
Rosario Santa Fe, 2000, Argentina More Info
Site 0200
Contact
Local Institution - 0213
Buenos Aires , 1425, Argentina More Info
Site 0213
Contact
Local Institution
Buenos Aires , C1431, Argentina More Info
Site 0162
Contact
Local Institution - 0214
Buenos Aires , CP128, Argentina More Info
Site 0214
Contact
Local Institution - 0248
Santa Fe , 3000, Argentina More Info
Site 0248
Contact
Local Institution - 0221
Box Hill Victoria, 3128, Australia More Info
Site 0221
Contact
Local Institution
Krems an der Donau , 3500, Austria More Info
Site 0008
Contact
Local Institution
Leoben , 8700, Austria More Info
Site 0024
Contact
Local Institution
Linz , 4020, Austria More Info
Site 0009
Contact
Local Institution
St. Pölten , 3100, Austria More Info
Site 0011
Contact
Local Institution
Wels , 4600, Austria More Info
Site 0023
Contact
Local Institution - 0206
Gent Oost-Vlaanderen, 9000, Belgium More Info
Site 0206
Contact
Local Institution - 0225
Greenfield Park Quebec, J4V 2, Canada More Info
Site 0225
Contact
Local Institution - 0222
Quebec City Quebec, G1J 1, Canada More Info
Site 0222
Contact
Local Institution - 0062
Beijing Beijing, 10002, China More Info
Site 0062
Contact
Local Institution - 0237
Xiamen Fujian, 36100, China More Info
Site 0237
Contact
Local Institution - 0238
Shenzhen Guangdong, 51803, China More Info
Site 0238
Contact
Local Institution - 0240
Nanning Guangxi, 53000, China More Info
Site 0240
Contact
Local Institution - 0111
Nanjing Jiangsu, 21000, China More Info
Site 0111
Contact
Local Institution - 0202
Kunming Yunnan, 65003, China More Info
Site 0202
Contact
Local Institution - 0254
Shijiazhuang , 05003, China More Info
Site 0254
Contact
Local Institution - 0256
Kuopio Pohjois-Savo, 70210, Finland More Info
Site 0256
Contact
Local Institution - 0175
Strasbourg Alsace, 67033, France More Info
Site 0175
Contact
Local Institution - 0091
Pessac Aquitaine, 33600, France More Info
Site 0091
Contact
Local Institution - 0205
Lyon CEDEX 08 Rhône-Alpes, 69373, France More Info
Site 0205
Contact
Local Institution
Clermont-Ferrand , 63100, France More Info
Site 0116
Contact
Local Institution
Lille , 59000, France More Info
Site 0146
Contact
Local Institution
Nantes , 44093, France More Info
Site 0043
Contact
Local Institution - 0216
Nîmes , 30029, France More Info
Site 0216
Contact
Local Institution
Rennes Cedex 02 , 35023, France More Info
Site 0057
Contact
Local Institution - 0188
Tours , 37032, France More Info
Site 0188
Contact
Local Institution - 0115
Paris Île-de-France, 75571, France More Info
Site 0115
Contact
Local Institution
Bonn , 53127, Germany More Info
Site 0092
Contact
Local Institution
Kiel , 24105, Germany More Info
Site 0058
Contact
Local Institution
Marburg , 35043, Germany More Info
Site 0059
Contact
Local Institution
Tuebingen , 72076, Germany More Info
Site 0010
Contact
Local Institution
Tuebingen , 72076, Germany More Info
Site 0015
Contact
Local Institution - 0251
Limerick , V94 F, Ireland More Info
Site 0251
Contact
Local Institution - 0212
Rome Roma, 00189, Italy More Info
Site 0212
Contact
Local Institution - 0258
Seoul Seoul-teukbyeolsi [Seoul], 05505, Korea, Republic of More Info
Site 0258
Contact
Local Institution
Busan , 49241, Korea, Republic of More Info
Site 0087
Contact
Local Institution
Hwasun , , Korea, Republic of More Info
Site 0085
Contact
Local Institution
Seongnam , 13620, Korea, Republic of More Info
Site 0102
Contact
Local Institution
Seongnam , 13620, Korea, Republic of More Info
Site 0086
Contact
Local Institution
Seoul , 03080, Korea, Republic of More Info
Site 0101
Contact
Local Institution
Seoul , 03080, Korea, Republic of More Info
Site 0081
Contact
Local Institution
Seoul , 03722, Korea, Republic of More Info
Site 0100
Contact
Local Institution
Seoul , 03722, Korea, Republic of More Info
Site 0090
Contact
Local Institution
Seoul , 06351, Korea, Republic of More Info
Site 0083
Contact
Local Institution
Seoul , 138-7, Korea, Republic of More Info
Site 0082
Contact
Local Institution
Seoul , , Korea, Republic of More Info
Site 0104
Contact
Local Institution
Seoul , , Korea, Republic of More Info
Site 0084
Contact
Local Institution - 0224
Torun Kujawsko-pomorskie, 87-10, Poland More Info
Site 0224
Contact
Local Institution - 0219
Warsaw Mazowieckie, 02-77, Poland
Local Institution - 0250
Warsaw Mazowieckie, 02-77, Poland More Info
Site 0250
Contact
Local Institution
Chorzów , 41-50, Poland More Info
Site 0185
Contact
Local Institution
Gdansk , 80214, Poland More Info
Site 0186
Contact
Local Institution
Lublin , 20-60, Poland More Info
Site 0187
Contact
Local Institution
Wroclaw , 50-36, Poland More Info
Site 0184
Contact
Local Institution - 0073
Barcelona Catalunya [Cataluña], 08036, Spain
Local Institution - 0210
Barcelona Catalunya [Cataluña], 08036, Spain More Info
Site 0210
Contact
Local Institution - 0252
Palma Illes Balears, 07120, Spain More Info
Site 0252
Contact
Local Institution - 0253
Marbella Málaga, 29603, Spain More Info
Site 0253
Contact
Local Institution - 0232
Ankara , 0, Turkey More Info
Site 0232
Contact
Local Institution - 0228
Istanbul , 34093, Turkey More Info
Site 0228
Contact
Local Institution - 0229
İzmir , 35100, Turkey More Info
Site 0229
Contact
Local Institution - 0226
Kayseri , 0, Turkey More Info
Site 0226
Contact
Local Institution - 0227
Samsun , 55139, Turkey More Info
Site 0227
Contact
Local Institution - 0218
Truro England, TR1 3, United Kingdom More Info
Site 0218
Contact
Local Institution - 0217
Stoke-on-Trent , ST4 6, United Kingdom More Info
Site 0217
Contact

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 3

Estimated Enrollment:

760

Study ID:

NCT05519085

Recruitment Status:

Recruiting

Sponsor:


Bristol-Myers Squibb

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.